Vanguard Group Inc. Boosts Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Vanguard Group Inc. lifted its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 0.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,021,906 shares of the medical device company’s stock after purchasing an additional 18,571 shares during the period. Vanguard Group Inc. owned about 10.70% of Tandem Diabetes Care worth $207,708,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Comerica Bank raised its position in shares of Tandem Diabetes Care by 15.1% during the 4th quarter. Comerica Bank now owns 34,364 shares of the medical device company’s stock worth $1,016,000 after purchasing an additional 4,520 shares during the last quarter. CenterBook Partners LP purchased a new position in shares of Tandem Diabetes Care in the fourth quarter valued at approximately $205,000. Capital International Sarl lifted its position in shares of Tandem Diabetes Care by 5.8% in the fourth quarter. Capital International Sarl now owns 56,242 shares of the medical device company’s stock valued at $1,664,000 after acquiring an additional 3,106 shares in the last quarter. KBC Group NV boosted its stake in shares of Tandem Diabetes Care by 256.1% in the fourth quarter. KBC Group NV now owns 239,944 shares of the medical device company’s stock worth $7,098,000 after acquiring an additional 172,570 shares during the last quarter. Finally, Alberta Investment Management Corp increased its position in shares of Tandem Diabetes Care by 8.7% during the fourth quarter. Alberta Investment Management Corp now owns 262,574 shares of the medical device company’s stock worth $7,767,000 after purchasing an additional 20,996 shares in the last quarter.

Insider Transactions at Tandem Diabetes Care

In related news, Director Dick Allen sold 5,000 shares of the business’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $51.68, for a total value of $258,400.00. Following the sale, the director now owns 24,396 shares in the company, valued at approximately $1,260,785.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Robert W. Baird lifted their target price on shares of Tandem Diabetes Care from $28.00 to $36.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Barclays upped their price objective on shares of Tandem Diabetes Care from $39.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, May 6th. Piper Sandler reissued an “overweight” rating and issued a $50.00 target price (up from $35.00) on shares of Tandem Diabetes Care in a research note on Friday, May 3rd. Oppenheimer upped their price target on Tandem Diabetes Care from $47.00 to $58.00 and gave the company an “outperform” rating in a research report on Monday, June 10th. Finally, SVB Leerink raised Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and increased their price target for the company from $34.00 to $45.00 in a report on Thursday, April 25th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.25.

Tandem Diabetes Care Trading Down 0.8 %

NASDAQ TNDM opened at $39.15 on Wednesday. The company has a debt-to-equity ratio of 1.43, a current ratio of 3.81 and a quick ratio of 3.01. The stock has a market capitalization of $2.53 billion, a P/E ratio of -18.04 and a beta of 1.28. The firm’s 50-day moving average is $44.76 and its two-hundred day moving average is $34.13. Tandem Diabetes Care, Inc. has a 12 month low of $13.82 and a 12 month high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, May 2nd. The medical device company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.17. Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 34.38%. The firm had revenue of $191.67 million for the quarter, compared to analyst estimates of $173.06 million. On average, sell-side analysts anticipate that Tandem Diabetes Care, Inc. will post -1.71 earnings per share for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.